Breast Conservation Therapy in Bilateral Malignant Breast Masses

Key Principles for Bilateral BCT

The European Society for Medical Oncology (ESMO) guidelines recommend that breast conservation therapy (BCT) is feasible and appropriate for patients with bilateral malignant breast masses, provided that clear surgical margins can be achieved in both breasts and the patient receives whole breast radiation therapy to both sides 1, 2.
Each breast must be evaluated independently for BCT candidacy based on tumor size relative to breast volume, tumor location, and ability to achieve negative margins 1, 2.
Clear resection margins (≥2 mm for DCIS, ≥1 mm for invasive cancer) must be achievable in both breasts without unacceptable cosmetic deformity 1, 2.

Postoperative whole breast radiation therapy is mandatory for both breasts following bilateral breast-conserving surgery for invasive cancer 2, 3.
Radiation reduces local recurrence risk by two-thirds and provides a survival benefit 2, 3.
Boost irradiation to the tumor bed is indicated for unfavorable risk factors including age <50 years, grade 3 tumors, vascular invasion, or focally positive margins 2, 3.

Prior chest wall irradiation (such as for lymphoma) makes bilateral BCT impossible due to inability to deliver therapeutic radiation doses to both breasts 1, 2.
Inability to achieve negative margins in either breast despite re-excision attempts 1, 2.
Multicentric disease (tumors in different quadrants) in either breast that cannot be encompassed in a single resection with acceptable cosmesis 1, 2.

BRCA1/2 mutation carriers can safely undergo BCT for bilateral breast cancer, but face a 25-31% 10-year risk of developing new contralateral breast cancer and should be counseled about bilateral mastectomy as an alternative 2, 3.
Radiation therapy is essential in BRCA carriers choosing BCT—omitting radiation results in high local recurrence rates 2, 3.
Genetic counseling is mandatory before finalizing surgical decisions 2, 3.

Patients with early-stage bilateral breast cancer should be informed that BCT outcomes may be equal to or better than mastectomy when properly selected 2, 3, 4.
The decision for bilateral mastectomy over BCT should follow thorough counseling about equivalent survival outcomes 2, 3, 4.

The ESMO guidelines consistently support breast conservation as the preferred local treatment for the majority of patients with invasive breast cancer, without specifically excluding bilateral disease 1, 2, 3.
Local recurrence rates with modern BCT techniques are equivalent to unifocal disease, with 4.5% recurrence rates at 3.5 years follow-up 1, 2, 3.

Never omit radiation therapy in patients choosing bilateral BCT—this is associated with unacceptably high local recurrence rates, particularly in high-risk populations 2, 3, 4.
Do not automatically recommend bilateral mastectomy simply because disease is bilateral—this represents overtreatment in appropriately selected candidates 2, 3, 4.
Ensure adequate margin assessment in both breasts, as positive margins significantly increase local recurrence risk 5.